Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland ChinaSHENGYING QIN; LU SHEN; GUOYIN FENG et al.Genomics (San Diego, Calif.). 2008, Vol 92, Num 3, pp 152-158, issn 0888-7543, 7 p.Article

CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish populationNIEWINSKI, P; ORZECHOWSKA-JUZWENKO, K; HURKACZ, M et al.European journal of clinical pharmacology. 2002, Vol 58, Num 8, pp 533-535, issn 0031-6970, 3 p.Article

Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicityCARMO, Helena; BRULPORT, Marc; SCHÖN, Michael R et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 11, pp 789-799, issn 1744-6872, 11 p.Article

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokineticsFURMAN, Katherine D; GRIMM, David R; MUELLER, Toby et al.Pharmacogenetics (London). 2004, Vol 14, Num 5, pp 279-284, issn 0960-314X, 6 p.Article

Towards a polymeric binding mimic for cytochrome CYP2D6RATHBONE, Daniel L; ALI, Aisha; ANTONAKI, Polyxeni et al.Biosensors & bioelectronics. 2005, Vol 20, Num 11, pp 2353-2363, issn 0956-5663, 11 p.Article

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humansEAP, Chin B; LESSARD, Etienne; BAUMANN, Pierre et al.Pharmacogenetics (London). 2003, Vol 13, Num 1, pp 39-47, issn 0960-314X, 9 p.Article

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteersKIRCHHEINERA, Julia; MEINEKE, Ingolf; MÜLLER, Gunnar et al.Pharmacogenetics (London). 2002, Vol 12, Num 7, pp 571-580, issn 0960-314X, 10 p.Article

The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjectsXIUJUN WU; LI YUAN; JINLIANG ZUO et al.European journal of clinical pharmacology. 2014, Vol 70, Num 1, pp 57-63, issn 0031-6970, 7 p.Article

Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classesDARWICH, Adam S; HENDERSON, Kathryn; BURGIN, Angela et al.British journal of clinical pharmacology. 2012, Vol 74, Num 5, pp 774-787, issn 0306-5251, 14 p.Article

Inhibition of CYP2D6- mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patientsCOLLER, Janet K; MICHALAKAS, Jennifer R; JAMES, Heather M et al.British journal of clinical pharmacology. 2012, Vol 74, Num 5, pp 835-841, issn 0306-5251, 7 p.Article

CYP2D6 Genotype and AdjuvantTamoxifen: Meta-Analysis of Heterogeneous Study PopulationsPROVINCE, M. A; GOETZ, M. P; MUSHIRODA, T et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 2, pp 216-227, issn 0009-9236, 12 p.Article

CYP2D6: novel genomic structures and allelesKRAMER, Whitney E; WALKER, Denise L; O'KANE, Dennis J et al.Pharmacogenetics and genomics (Print). 2009, Vol 19, Num 10, pp 813-822, issn 1744-6872, 10 p.Article

Genotype and allele frequency of CYP2D6 in Tamilian populationADITHAN, C; GERARD, N; NAVEEN, A. T et al.European journal of clinical pharmacology. 2003, Vol 59, Num 7, pp 517-520, issn 0031-6970, 4 p.Article

Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scalesSISTONEN, Johanna; FUSELLI, Silvia; PALO, Jukka U et al.Pharmacogenetics and genomics (Print). 2009, Vol 19, Num 2, pp 170-179, issn 1744-6872, 10 p.Article

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structureSISTONEN, Johanna; SAJANTILA, Antti; LAO, Oscar et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 2, pp 93-101, issn 1744-6872, 9 p.Article

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in plateletsKIRCHHEINER, Julia; HENCKEL, Hanns-Benjamin; FRANKE, Leonora et al.Pharmacogenetics and genomics (Print). 2005, Vol 15, Num 8, pp 579-587, issn 1744-6872, 9 p.Article

Population pharmacokinetic analysis of mirtazapineGRASMÄDER, Katja; VERWOHLT, Petra Louise; RAO, Marie Luise et al.European journal of clinical pharmacology. 2004, Vol 60, Num 7, pp 473-480, issn 0031-6970, 8 p.Article

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and CodeineTherapy: 2014 UpdateCREWS, K. R; GAEDIGK, A; PROWS, C. A et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 4, pp 376-382, issn 0009-9236, 7 p.Article

New allelic arrangement CYP2D6*36×2 found in a Japanese poor metabolizer of debrisoquineCHIDA, Michihiro; ARIYOSHI, Noritaka; YOKOI, Tsuyoshi et al.Pharmacogenetics (London). 2002, Vol 12, Num 8, pp 659-662, issn 0960-314X, 4 p.Article

Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian populationISAZA, C. A; HENAO, J; LOPEZ, A. M et al.Methods and findings in experimental and clinical pharmacology. 2000, Vol 22, Num 9, pp 695-705, issn 0379-0355Article

Dynamics and persistence of CYP2D6 inhibition by paroxetineJUŘICA, J; ŽOURKOVA, A.Journal of clinical pharmacy and therapeutics (Print). 2013, Vol 38, Num 4, pp 294-300, issn 0269-4727, 7 p.Article

Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer statusBARCLAY, Murray L; SAWYERS, Steven M; BEGG, Evan J et al.Pharmacogenetics (London). 2003, Vol 13, Num 10, pp 627-632, issn 0960-314X, 6 p.Article

Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6HAERTTER, Sebastian.Drug metabolism and drug interactions. 2013, Vol 28, Num 4, pp 209-216, issn 0792-5077, 8 p.Conference Paper

CYP2D6*4 polymorphism is associated with statin-induced muscle effectsFRUDAKIS, Tony N; THOMAS, Matthew J; GINJUPALLI, Siva N et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 9, pp 695-707, issn 1744-6872, 13 p.Article

CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genesSIM, Sarah C; DALY, Ann K; GAEDIGK, Andrea et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 9, pp 692-694, issn 1744-6872, 3 p.Article